Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2025-03-11 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
昆药集团十一届二次董事会决议公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of resolutions passed at the company's eleventh second board meeting, including approvals of various reports and plans for the 2024 fiscal year, such as the president's work report, business plan, board work report, audit and risk control committee report, independent directors' report, internal control evaluation, internal audit, financial statements, profit distribution plan, and other related matters. It also mentions that some reports are published on the Shanghai Stock Exchange website and that certain proposals require shareholder meeting approval. The document is not the reports themselves but a formal announcement of board meeting decisions and approvals. The length is 3294 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best as a Regulatory Filing (RNS) because it is a formal regulatory announcement of board resolutions and related approvals, not the full annual report or audit report itself.
2025-03-11 Chinese
昆药集团2024年度审计报告
Regulatory Filings
2025-03-11 Chinese
关于昆药集团2024年度非经营性资金占用及其他关联资金往来情况汇总表的专项审核报告
Regulatory Filings
2025-03-11 Chinese
昆药集团2024年年度报告
Annual Report Classification · 100% confidence The document is titled "昆药集团股份有限公司 2024 年年度报告" which translates to "KPC Pharmaceuticals, Inc. 2024 Annual Report." It contains detailed sections typical of an annual report, including company overview, financial data for multiple years, management discussion and analysis, corporate governance, environmental and social responsibility, and audited financial statements. The document includes signatures from company officers and an audit report from KPMG Huazhen, indicating it is a full official annual report. The length of the document (15,000 characters) and the detailed financial and operational data confirm it is not merely an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K).
2025-03-11 Chinese
昆药集团2024年度独立董事述职报告（辛金国）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2024 by an independent director of Kunming Pharmaceutical Group Co., Ltd. It details the director's duties, attendance at board and shareholder meetings, committee work, oversight of related party transactions, external guarantees, use of raised funds, remuneration, share repurchase, appointment of auditors, accounting policy changes, dividend distribution, asset impairment provisions, information disclosure, and internal control execution. The content is a detailed narrative of the independent director's work and oversight during the fiscal year 2024, which aligns with a management or board-related report rather than a full annual report or audit report. It is not a transcript, earnings release, or regulatory filing. The document is comprehensive and substantive, not a brief announcement or certification. Therefore, it fits best under the category of Board/Management Information (MANG), which includes announcements of changes or reports related to the company's board or senior management activities, including independent directors' reports.
2025-03-11 Chinese
昆药集团关于2024年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a special report on the storage and actual use of raised funds for the year 2024 by Kunming Pharmaceutical Group Co., Ltd. It references regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange regarding the management and use of raised funds. The content details the amounts raised through various stock issuances (initial public offering, additional issuance, and private placement), the use of these funds over multiple years, the management system for the raised funds, and specific investment projects funded by these raised funds. It also includes detailed tables of fund usage, investment projects, and cash management of idle raised funds. The document is comprehensive, contains actual financial data and analysis related to fundraising and fund usage, and is not merely an announcement or a certification. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. Therefore, the appropriate classification is CAP.
2025-03-11 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.